LXEONasdaq

Lexeo Therapeutics, Inc.

Healthcare·Oncology·Phase 3·New York, NY, United States
OncologyRare DiseaseGene TherapyNeurologyImmunologyCardiovascular

Lexeo Therapeutics, Inc. (LXEO): 8 pipeline candidates · ~27 mo cash runway · 8 clinical trials. Updated within the last hour.

6.8/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway7.6

27.2 months

Financial Health8.9

D/E 0.08 · 10% dilution

Pipeline Maturity6.0

Lead: Phase 1/Phase 2

Pipeline Breadth10.0

8 candidates

Catalyst MomentumN/A

N/A

Insider Signal1.5

0 buys · 5 sells (180d)

A transparent, data-derived signal for Lexeo Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$391.0M

Cash

$75.0M

Quarterly Burn

$21.1M

Runway

27.2 mo

Revenue

—

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Sep 2028
Today~30 mo out
Catalyst within runway

Pipeline (8 candidates)

DrugPhase
high dose lx2006Phase 1/Phase 2
low dose lx2006Phase 1/Phase 2
lx1001Phase 1
lx2006Phase 2
lx2020Phase 1/Phase 2
lx2021Phase 1/Phase 2
lx2022Phase 1/Phase 2
mid dose lx2006Phase 1/Phase 2
8 clinical trials·1 FDA decision·CEO: Mr. R. Nolan Townsend M.B.A.

Frequently asked questions

How many drug candidates are in Lexeo Therapeutics, Inc.'s pipeline?

Lexeo Therapeutics, Inc. (LXEO) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Lexeo Therapeutics, Inc.'s lead drug candidate?

Lexeo Therapeutics, Inc.'s most advanced tracked candidate is high dose lx2006 (Phase 1/Phase 2) for Friedreich Ataxia.

What is Lexeo Therapeutics, Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Lexeo Therapeutics, Inc. has approximately 27.2 months of cash runway.

What is Lexeo Therapeutics, Inc.'s market capitalization?

Lexeo Therapeutics, Inc.'s market capitalization is approximately $391.0M.

Who is the CEO of Lexeo Therapeutics, Inc.?

Mr. R. Nolan Townsend M.B.A. is the chief executive officer of Lexeo Therapeutics, Inc. (LXEO).

Get the full picture on Lexeo Therapeutics, Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar